Hpatinib, a heavyweight innovative drug of Hengrui medicine, will be on the market within the year

According to the report on June 12, Hengrui medicine received a notice from the drug audit center of the State Food and Drug Administration (CFDA), and the company can apply to CFDA for on-site inspection of apatinib production Insiders of the company expect to be available for sale within the year It is understood that apatinib is a major special drug, which is suitable for cancer patients after the failure of other treatment methods At present, there is no domestic enterprise with the production approval document of the drug, and only Hengrui pharmaceutical is applying for production It is generally expected that the potential market size of apatinib gastric cancer indications will exceed 1 billion yuan The incidence rate of gastric cancer is 30.2/10 million in China, ranking third in the incidence rate of malignant tumors, and 400 thousand cases in new cases each year Apatinib will be the first oral kinase inhibitor for targeted treatment of advanced gastric cancer Meanwhile, the indication of apatinib is still in clinical practice.